Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMART-KEY: Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx Cancers
NCT04943445Phase 2Completed
- Sponsor
- Latin American Cooperative Oncology Group
- Start
- Feb 2022
- Primary completion
- Aug 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in squamous cell carcinoma of the larynx (SCCL), sponsored by Latin American Cooperative Oncology Group. Started Feb 2022; status: completed.
02
Drugs
03
Conditions
squamous cell carcinoma of the larynx (SCCL)
Beyond the preview
Go deeper on NCT04943445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04943445.